Silence Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Silence Therapeutics CEO'su Craig Tooman, Feb2022 tarihinde atandı, in görev süresi 2.75 yıldır. in toplam yıllık tazminatı £ 7.30M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.5% maaş ve 93.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.024% ine doğrudan sahiptir ve bu hisseler $ 78.94K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.1 yıl ve 4.8 yıldır.

Anahtar bilgiler

Craig Tooman

İcra Kurulu Başkanı

UK£7.3m

Toplam tazminat

CEO maaş yüzdesi	6.5%
CEO görev süresi	2.8yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	2.1yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio

Oct 04

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 18

Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit

Jun 17

Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

May 21

Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues

Feb 07

Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%

Nov 27

CEO Tazminat Analizi

Craig Tooman'un ücretlendirmesi Silence Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-UK£59m
Jun 30 2024	n/a	n/a	-UK£40m
Mar 31 2024	n/a	n/a	-UK£35m
Dec 31 2023	UK£7m	UK£473k	-UK£43m
Sep 30 2023	n/a	n/a	-UK£43m
Jun 30 2023	n/a	n/a	-UK£41m
Mar 31 2023	n/a	n/a	-UK£43m
Dec 31 2022	UK£6m	UK£461k	-UK£40m
Sep 30 2022	n/a	n/a	-UK£36m
Jun 30 2022	n/a	n/a	-UK£39m
Mar 31 2022	n/a	n/a	-UK£39m
Dec 31 2021	UK£2m	UK£334k	-UK£39m

Tazminat ve Piyasa: Craig 'nin toplam tazminatı ($USD 9.17M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.14M ).

Tazminat ve Kazançlar: Craig şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Craig Tooman (59 yo)

2.8yrs

Görev süresi

UK£7,298,000

Tazminat

Mr. Craig A. Tooman, MBA, serves as President, Chief Executive Officer and Executive Director of Silence Therapeutics plc since February 21, 2022. He has been a Supervisory Director of Curevac N. V. since...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Craig Tooman	President	2.8yrs	UK£7.30m	0.024% $ 78.9k
Rhonda Hellums	Executive VP	2.8yrs	UK£2.50m	0.0011% $ 3.5k
Steven Romano	Executive VP and Chief Research & Development Officer	1.6yrs	UK£1.82m	0.0092% $ 30.6k
Marie Lindholm	Chief Scientific Officer	less than a year	Veri yok	Veri yok
Gem Hopkins	Head of IR & Corporate Communications	no data	Veri yok	Veri yok
Gianine Esposito	Chief Human Resources Officer	less than a year	Veri yok	Veri yok
Barbara Ruskin	Senior VP and Chief Intellectual Property & Innovation Officer	2.2yrs	Veri yok	Veri yok
Eric Floyd	Senior Vice President of Regulatory Affairs & Quality Assurance	4.3yrs	Veri yok	Veri yok
J.P. Gabriel	Chief Technical Operations Officer	2yrs	Veri yok	Veri yok
Curtis Rambaran	Chief Medical Officer	no data	Veri yok	Veri yok

2.1yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: SLN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Craig Tooman	President	2.8yrs	UK£7.30m	0.024% $ 78.9k
David Lemus	Independent Non-Executive Director	6.4yrs	UK£184.00k	0.0054% $ 17.7k
Gordon Duff	Chairman of Scientific Advisory Board	4.8yrs	Veri yok	Veri yok
Michael Davidson	Independent Non-Executive Director	3.8yrs	UK£178.00k	0.0092% $ 30.6k
Iain Ross	Independent Chairman of the Board	5.6yrs	UK£402.00k	0.078% $ 259.2k
John Porter	Member of Scientific Advisory Board	4.8yrs	Veri yok	Veri yok
James Ede-Golightly	Independent Non-Executive Director	5.6yrs	UK£182.00k	0.011% $ 35.3k
Henry Ginsberg	Member of Scientific Advisory Board	4.8yrs	Veri yok	Veri yok
Annemieke Aartsma-Rus	Member of Scientific Advisory Board	4.8yrs	Veri yok	Veri yok
John Whittaker	Member of Scientific Advisory Board	4.4yrs	Veri yok	Veri yok
Jenny Sims	Member of Scientific Advisory Board	2.8yrs	Veri yok	Veri yok
Tom Brown	Member of Scientific Advisory Board	2.8yrs	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SLN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Silence Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024

Silence Therapeutics plc, Annual General Meeting, May 17, 2024

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Announces Retirement of Giles Campion as Chief Medical Officer, Head of Research & Development and Member of Board

Silence Therapeutics plc Announces Executive Changes

Recent updates

Silence Therapeutics plc Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics plc Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(A)

Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit

Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024

Silence Therapeutics plc, Annual General Meeting, May 17, 2024

Silence Therapeutics plc Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

Silence Therapeutics plc Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(A)

Silence Therapeutics plc to Report Q4, 2023 Results on Mar 13, 2024

Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues

Price target increased by 16% to US$49.40

Silence Therapeutics plc Announces Executive Changes

Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%

Silence Therapeutics plc Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Silence Therapeutics plc Announces Retirement of Giles Campion as Chief Medical Officer, Head of Research & Development and Member of Board

New major risk - Share price stability

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Provides SLN360 and SLN124 Clinical Program Updates

Silence Therapeutics plc Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

Silence Therapeutics plc Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera

Silence Therapeutics wins FDA’s fast track status for blood cancer therapy

Silence Therapeutics prices 5.95M ADSs at $9.50/share

Silence Therapeutics plc, Annual General Meeting, Jun 14, 2022

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting

Silence Therapeutics plc to Report Q4, 2021 Results on Mar 17, 2022

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)

Silence Therapeutics plc Presents Additional Positive Data from the SLN124 Healthy Volunteer Study

Silence Therapeutics Updates on AIM Delisting

Silence Therapeutics plc announced that it has received $40 million in funding from AstraZeneca PLC

Silence Therapeutics plc Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers

Silence Therapeutics plc to Report Fiscal Year 2020 Results on Mar 30, 2021

Silence Therapeutics plc & Mallinckrodt plc Initiate Work on 3Rd Target

Silence Therapeutics plc announced that it has received $45.499905 million in funding from a group of investors

Silence Therapeutics plc Initiates Dosing in Phase 1 Clinical Trial of Sln360 for Cardiovascular Disease Due to High Lipoprotein(A)

Silence Therapeutics Appoints Michael H. Davidson to Board of Directors

Silence Therapeutics Appoints Craig Tooman as CFO

New finance chief for Silence Therapeutics

Silence Therapeutics plc Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) At American Heart Association 2020

Silence Therapeutics plc Appoints Marie Wikström Lindholm as Senior Vice President, Molecular Design and Member of the Silence Executive Leadership Team

Silence Therapeutics plc Announces Rob Quinn, the Current CFO Will Leave the Company in January 2021

Silence Therapeutics plc announced that it has received $20 million in funding from AstraZeneca PLC

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş